HOME >> MEDICINE >> NEWS
Mouse model of neuromuscular disease identifies key player in motor neuron death

Scientists have created a new mouse model for spinal and bulbar muscular atrophy (SBMA), a disease characterized by adult-onset progressive weakness and degeneration of limb muscles, often resulting in the patient being confined to a wheel chair. SBMA causes the death of cells called motor neurons that control muscle function. The study, published in the March 4 issue of Neuron, presents a clearer picture of the pathology underlying SBMA and associated diseases and even points to a possible therapeutic strategy for this debilitating condition and for more common motor neuron diseases, such as amyotrophic lateral sclerosis (ALS), that currently have no proven treatments.

SBMA belongs to a group of neurodegenerative disorders, called polyglutamine diseases, that includes Huntington's disease and spinocerebellar ataxias. Polyglutamine diseases are thought to arise because of a mutant protein that is misfolded and subsequently clumps together to form toxic aggregates that destroy cell function and cause disease. In SBMA, a mutated gene directs production of androgen receptors with an abnormal number of consecutive residues of the amino acid glutamine. Dr. Albert R. La Spada and colleagues from the University of Washington Medical Center in Seattle created transgenic mice containing the human androgen receptor carrying 100 glutamine repeats. The mice developed a gradually progressive limb weakness around mid-adulthood that was accompanied by motor neuron degeneration, strikingly similar to what is seen in human SBMA patients. The researchers determined that the abnormal androgen receptor interfered with production of a molecule called vascular endothelial growth factor (VEGF) that is important for the general health and survival of motor neurons. Interestingly, VEGF could rescue SBMA-like motor neurons grown in the laboratory.

The researchers conclude that VEGF may play a pivotal role in motor neuron degeneration. "Our findings in SBMA suggest that
'"/>

Contact: Heidi Hardman
hhardman@cell.com
617-397-2879
Cell Press
3-Mar-2004


Page: 1 2

Related medicine news :

1. Mouse model reveals potential way to reduce cardiac deaths in kidney patients
2. Mouse gene shows new mechanism behind cardiac infarction in man
3. Mouse model gives insight to human hair loss
4. Mouse study: Signal overload in Alzheimer brains
5. Mouse shows how Rituximab removes human B cells
6. Mouse study could aid vaccine designers
7. Mouse model mimics real-world plague infection
8. Mouse antibodies thwart SARS virus
9. Mouse study gives new view of anthrax toxin
10. Mouse studies reveal immune mechanism involved in bone loss caused by estrogen deficiency
11. Mouse provides clues about chronic pain

Post Your Comments:
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... According to ... been developed that changes color when subjected to an impact force that is great ... be implemented in helmets or other sporting equipment so that coaches or officials would ...
(Date:9/4/2015)... ... September 04, 2015 , ... According to an article published August ... Association presented data showing that it is safe for pregnant women to undergo local ... had undergone local anesthesia with a group that hadn’t, researchers were able to determine ...
(Date:9/4/2015)... ... September 04, 2015 , ... On ... has effectively doubled the size of its annual health tech innovation program. Now ... digital health startups to compete for cash and prizes to advance their technologies ...
(Date:9/4/2015)... , ... September 04, 2015 , ... With TransCel from ... mouse all within Final Cut Pro X. With TransCel users have full control over ... width, background color, speed method, frame color, inner color, text, and more. With TransCel ...
(Date:9/4/2015)... ... 2015 , ... Mile High Connects today releases “First and Last Mile Connections,” ... sidewalks, bike paths, and other vital supports severely limit access to public transportation for ... dollars to expand public transit, there’s very little support for safe and convenient access ...
Breaking Medicine News(10 mins):Health News:New Article on Head Injury Detection Technology Highlights Implications for Head Injury Detection in Sports, says The Law Offices of Burg & Brock 2Health News:Recent Study on Dental Care During Pregnancy Demonstrates How Preventative Dental Care Really is for Everyone, Says Medical Center Dental Care 2Health News:Insight Product Development Startup Competition on Track to Double Program Impact 2Health News:Insight Product Development Startup Competition on Track to Double Program Impact 3Health News:Pixel Film Studios Releases TransCel, a New FCPX Transition 2Health News:Missed Connections in Metro Denver Transit 2
(Date:9/4/2015)... , Sept. 4, 2015  Janssen Research & ... and Drug Administration (FDA) has accepted for Priority ... as a treatment for patients with multiple myeloma ... (PI) and an immunomodulatory agent (IMiD), or who ... therapy, including a PI and an IMiD. This ...
(Date:9/4/2015)... -- Fair Rate Funding, a lawsuit funding firm located in ... increase in lawsuit filings in connection with the blood thinning ... Philadelphia Court of Common Pleas has ... Louisiana multi---district litigation (MDL), located in ... Louisiana , the filings are also on the ...
(Date:9/4/2015)... HILL, N.C. , Sept. 4, 2015 /PRNewswire/ ... Liaisons (MSLs) and other Field-Based Medical Specialists (FBMS) ... key opinion leaders, and thought leaders in critical ... effectiveness of their field-based teams, companies are expanding ... order to align countries with corporate objectives and ...
Breaking Medicine Technology:U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 2U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 3U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 4U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 5U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 6U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 7Xarelto Lawsuit Funding Firm, Fair Rate Funding Reports a Steady Rise in Xarelto Product Liability Lawsuit Filings 2Xarelto Lawsuit Funding Firm, Fair Rate Funding Reports a Steady Rise in Xarelto Product Liability Lawsuit Filings 3New Study Presents Tactics and Insights on How to Effectively Globalize Medical Science Liaison Programs in the Pharmaceutical Industry 2
Cached News: